RxDoctor Payments Data

Nishtha Sodhi, MD

Cardiovascular Disease · Saint Paul, MNNPI 1467744326

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (46.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Medtronic at 53.3% of the total. Reporting peaked in 2022 at $28,013 and has fallen 97.1% since, to $825 in 2025.

$49,905in general payments, 2019–2025

Across 170 payments — averaging $293.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$27K
  • Edwards Lifesciences$11K
  • Ethicon Endo-surgery Inc.$7K
  • Boston Scientific$3K
  • Abbott$3K
  • Philips North America LLC$332
  • plus $237 from 4 others
$65,066in research payments, 2019–2025

Across 25 payments — averaging $2602.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • W. L. Gore & Associates, Inc.$64K
  • Medtronic$850

What the payments were for

  • Consulting fees$10,69521%
  • Speaking & faculty fees$23,01346%
  • Travel & lodging$9,60119%
  • Food & beverage$6,59613%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$49,905 in reported general payments places this provider in the 85th percentile of 451 cardiovascular disease providers in Minnesota.

See all cardiovascular disease providers in Minnesota →

Medicare billing

Part B allowed, 2024
$33,252
Medicare patients
82
Services billed
248

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban37$54,901
Metoprolol Succinate31$493
ClopidogrelClopidogrel Bisulfate29$442
Atorvastatin Calcium16$305
Nitroglycerin26$270
Metoprolol Tartrate13$191
Amlodipine Besylate11$180
Lisinopril12$168
Furosemide12$26

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Saint Paul

See the full list for Minnesota →

Where these figures come from

Is this you, or does something look wrong? →